FDA Approves Baxdrostat for Resistant Hypertension - Quiz - MDSpire

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Baxdrostat for Resistant Hypertension

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

Real-world follow-up data from 465 patients add to evidence from earlier randomized trials.

Iron deficiency in primary care patients with heart failure: a cross-sectional study of the heart failure in Southern Sweden (HISS) cohort

Treatment of mild subclinical hypothyroidism and its impact on lipid metabolism